FindTrial
Sign In

PRT1419

DRUG3 trials

Sponsors

Prelude Therapeutics

Conditions

Acute Myeloid LeukemiaB-cell Non-Hodgkin LymphomaBreast CancerCervical CancerChronic Lymphocytic LeukemiaChronic Myelomonocytic LeukemiaEsophageal CancerFollicular Lymphoma

Phase 1

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
CompletedNCT04543305
Prelude TherapeuticsAcute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes +1
Start: 2020-09-28End: 2022-03-21Updated: 2022-11-15
A Study of PRT1419 in Patients With Advanced Solid Tumors
CompletedNCT04837677
Prelude TherapeuticsBreast Cancer, Cervical Cancer, Esophageal Cancer +4
Start: 2021-08-11End: 2023-02-06Updated: 2023-03-15
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
TerminatedNCT05107856
Prelude TherapeuticsAcute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia +7
Start: 2022-03-22End: 2024-01-19Updated: 2024-01-31

Related Papers

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
Communications Medicine2023-10-2552 citations
Abstract CT172: A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced/metastatic solid tumors
Cancer Research2023-04-1410 citations
Abstract 983: Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1
Cancer Research2021-07-0116 citations